Structure of the human histamine H 1 receptor complex with doxepin

Nature

Volumn 475, Issue 7354, 2011, Pages 65-72

  Shimamura, Tatsuro ^a,b,c   Shiroishi, Mitsunori ^a,b,d   Weyand, Simone ^a,e,f   Tsujimoto, Hirokazu ^a,b   Winter, Graeme ^f   Katritch, Vsevolod ^g   Abagyan, Ruben ^g   Cherezov, Vadim ^c   Liu, Wei ^c   Han, Gye Won ^c   Kobayashi, Takuya ^a,b   Stevens, Raymond C ^c   Iwata, So ^a,b,e,f,h  

^a JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

^d KYUSHU UNIVERSITY   (Japan)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f DIAMOND LIGHT SOURCE LTD   (United Kingdom)

^g UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^h RIKEN   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACRIVASTINE; DOXEPIN; FEXOFENADINE; G PROTEIN COUPLED RECEPTOR; HISTAMINE; HISTAMINE H1 RECEPTOR; HISTAMINE H1 RECEPTOR ANTAGONIST; LEVOCETIRIZINE; OLOPATADINE;

BIOCHEMISTRY; CRYSTAL STRUCTURE; DRUG; HOMINID; HYDROPHOBICITY; ION; LIGAND; MOLECULAR ANALYSIS; PATHOLOGY; PHOSPHATE; PROTEIN; SYMPTOM;

ALLERGY; ARTICLE; BINDING AFFINITY; COMPLEX FORMATION; CRYSTAL STRUCTURE; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; HUMAN; HYDROGEN BOND; INFLAMMATION; ISOMER; LIGAND BINDING; MOLECULAR INTERACTION; MOLECULE; PICHIA PASTORIS; PRIORITY JOURNAL; X RAY DIFFRACTION;

BINDING SITES; CRYSTALLOGRAPHY, X-RAY; DOXEPIN; HISTAMINE ANTAGONISTS; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; ISOMERISM; LIGANDS; MODELS, MOLECULAR; PHOSPHATES; PROTEIN BINDING; PROTEIN CONFORMATION; RECEPTORS, ADRENERGIC, BETA-2; RECEPTORS, DOPAMINE D3; RECEPTORS, HISTAMINE H1; SUBSTRATE SPECIFICITY;

EID: 79960070651     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature10236     Document Type: Article

References (59)

1. Schwartz, J. C., Arrang, J. M., Garbarg, M., Pollard, H. & Ruat, M. Histaminergic transmission in the mammalian brain. Physiol. Rev. 71, 1-51 (1991).
2. Hill, S. J. Distribution, properties, and functional characteristics of three classes of histamine receptor. Pharmacol. Rev. 42, 45-83 (1990). (Pubitemid 20209593)
3. Hill, S. J. et al. International Union of Pharmacology. XIII. Classification of histamine receptors. Pharmacol. Rev. 49, 253-278 (1997). (Pubitemid 27414915)
4. Yamashita, M. et al. Expression cloning of a cDNA encoding the bovine histamine H1 receptor. Proc. Natl Acad. Sci. USA 88, 11515-11519 (1991). (Pubitemid 21916072)
5. Simons, F. E. Advances in H1-antihistamines. N. Engl. J. Med. 351, 2203-2217 (2004).
6. Overington, J. P., Al-Lazikani, B. & Hopkins, A. L. How many drug targets are there? Nature Rev. Drug Discov. 5, 993-996 (2006). (Pubitemid 44835126)
7. Bakker, R. A., Wieland, K., Timmerman, H. & Leurs, R. Constitutive activity of the histamine H1 receptor reveals inverse agonism of histamine H1 receptor antagonists. Eur. J. Pharmacol. 387, R5-R7 (2000). (Pubitemid 30035384)
8. Bakker, R. A., Schoonus, S. B.,Smit, M. J., Timmerman, H. & Leurs, R. HistamineH1- receptor activation of nuclear factor-kB: roles for Gbc- and Gaq/11-subunits in constitutive and agonist-mediated signaling. Mol. Pharmacol. 60, 1133-1142 (2001). (Pubitemid 33027449)
9. Tashiro, M. et al. Dose dependency of brain histamine H1 receptor occupancy following oral administration of cetirizine hydrochloride measured using PET with [11C]doxepin. Hum. Psychopharmacol. 24, 540-548 (2009).
10. Woosley, R. L., Chen, Y., Freiman, J. P. & Gillis, R. A. Mechanism of the cardiotoxic actions of terfenadine. J. Am. Med. Assoc. 269, 1532-1536 (1993). (Pubitemid 23086414)
11. Yap, Y. G. & Camm, A. J. Potential cardiac toxicity ofH1-antihistamines. Clin. Allergy Immunol. 17, 389-419 (2002).
12. Okamura, N. et al. Functional neuroimaging of cognition impaired by a classical antihistamine, d-chlorpheniramine. Br. J. Pharmacol. 129, 115-123 (2000). (Pubitemid 30072677)
13. Cusack, B., Nelson, A. & Richelson, E. Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl.) 114, 559-565 (1994). (Pubitemid 24152135)
14. Sarker, S. et al. The high-affinity binding site for tricyclic antidepressants resides in the outer vestibule of the serotonin transporter. Mol. Pharmacol. 78, 1026-1035 (2010).
15. Klabunde, T. & Hessler, G. Drug design strategies for targeting G-protein-coupled receptors. Chem Bio Chem 3, 928-944 (2002). (Pubitemid 35189597)
16. de Graaf, C., Rognan, D. & Customizing, G. Protein-coupled receptor models for structure-based virtual screening. Curr. Pharm. Des. 15, 4026-4048 (2009).
17. Palczewski, K. et al. Crystal structure of rhodopsin: a G protein-coupled receptor. Science 289, 739-745 (2000). (Pubitemid 30650186)
18. Cherezov, V. et al. High-resolution crystal structure of an engineered human b2- adrenergic G protein-coupled receptor. Science 318, 1258-1265 (2007). (Pubitemid 350172884)
19. Warne, T. et al. Structure of a b1-adrenergic G-protein-coupled receptor. Nature 454, 486-491 (2008).
20. Jaakola, V. P. et al. The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science 322, 1211-1217 (2008).
21. Murakami, M. & Kouyama, T. Crystal structure of squid rhodopsin. Nature 453, 363-367 (2008). (Pubitemid 351693128)
22. Wu, B. et al. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 330, 1066-1071 (2010).
23. Chien, E. Y. et al. Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Science 330, 1091-1095 (2010).
24. Kolb, P. et al. Structure-based discovery of b2-adrenergic receptor ligands. Proc. Natl Acad. Sci. USA 106, 6843-6848 (2009).
25. Katritch, V. et al. Structure-based discovery of novel chemotypes for adenosine A2A receptor antagonists. J. Med. Chem. 53, 1799-1809 (2010).
26. Rosenbaum, D. M. et al. GPCR engineering yields high-resolution structural insights into b2-adrenergic receptor function. Science 318, 1266-1273 (2007). (Pubitemid 350172885)
27. Ratnala, V. R. et al. Large-scale overproduction, functional purification and ligand affinities of the His-tagged human histamine H1 receptor. Eur. J. Biochem. 271, 2636-2646 (2004). (Pubitemid 38869965)
28. Ballesteros, J. A. & Weinstein, H. Integrated methods for the construction of threedimensionalmodels and computational probing of structure-function relations in G protein-coupled receptors. Methods Neurosci. 25, 366-428 (1995).
29. Qanbar, R. & Bouvier, M. Role of palmitoylation/depalmitoylation reactions in G-protein-coupled receptor function. Pharmacol. Ther. 97, 1-33 (2003). (Pubitemid 35477802)
30. Wieland, K. et al.Mutationalanalysis of the antagonist-binding site of the histamine H1 receptor. J. Biol. Chem. 274, 29994-30000 (1999).
31. Ohta, K. et al. Site-directed mutagenesis of the histamine H1 receptor: roles of aspartic acid107, asparagine198 and threonine194. Biochem. Biophys. Res. Commun. 203, 1096-1101 (1994).
32. Nonaka, H. et al. Unique binding pocket forKW-4679 in the histamineH1 receptor. Eur. J. Pharmacol. 345, 111-117 (1998). (Pubitemid 28179478)
33. Bruysters, M. et al. Mutational analysis of the histamine H1-receptor binding pocket of histaprodifens. Eur. J. Pharmacol. 487, 55-63 (2004). (Pubitemid 38368981)
34. Peeters, M. C., van Westen, G. J., Li, Q. & Ijzerman, A. P. Importance of the extracellular loops in G protein-coupled receptors for ligand recognition and receptor activation. Trends Pharmacol. Sci. 32, 35-42 (2011).
35. Gillard, M. et al.H1 antagonists: receptor affinity versus selectivity. Inflamm. Res. 52 (Suppl. 1), S49-S50 (2003). (Pubitemid 36470055)
36. Kiss, R.,Kovari, Z. & Keseru, G. M.Homologymodellingandbinding sitemappingof the human histamine H1 receptor. Eur. J. Med. Chem. 39, 959-967 (2004). (Pubitemid 39389106)
37. Jongejan, A. & Leurs, R. Delineation of receptor-ligand interactions at the human histamine H1 receptor by a combined approach of site-directedmutagenesis and computational techniques-or-how to bind the H1 receptor. Arch. Pharm. (Weinheim) 338, 248-259 (2005). (Pubitemid 40957263)
38. Totrov, M. & Abagyan, R. Flexible protein-ligand docking by global energy optimization in internal coordinates. Proteins (Suppl. 1) 29, 215-220 (1997). (Pubitemid 28090502)
39. Katritch, V. et al. Analysis of full and partial agonists binding to b2-adrenergic receptor suggests a role of transmembrane helix V in agonist-specific conformational changes. J. Mol. Recognit. 22, 307-318 (2009).
40. Katritch, V., Kufareva, I. & Abagyan, R. Structure based prediction of subtypeselectivity for adenosine receptor antagonists. Neuropharmacology 60, 108-115 (2011).
41. Matsumoto, Y., Funahashi, J., Mori, K., Hayashi, K. & Yano, H. The noncompetitive antagonism of histamine H1 receptors expressed in Chinese hamster ovary cells by olopatadine hydrochloride: its potency and molecular mechanism. Pharmacology 81, 266-274 (2008). (Pubitemid 351450420)
42. Gillard, M., Van Der Perren, C., Moguilevsky, N., Massingham, R. & Chatelain, P. Binding characteristics of cetirizine and levocetirizine to human H1 histamine receptors: contribution of Lys191 andThr194.Mol. Pharmacol. 61, 391-399(2002). (Pubitemid 34112814)
43. Leurs, R., Smit, M. J.,Meeder, R., Ter Laak, A. M. & Timmerman, H. Lysine200 located in the fifth transmembrane domain of the histamine H1 receptor interacts with histamine but not with all H1 agonists. Biochem. Biophys. Res. Commun. 214, 110-117 (1995).
44. Bakker, R. A. et al. 8R-lisuride is a potent stereospecific histamine H1-receptor partial agonist. Mol. Pharmacol. 65, 538-549 (2004). (Pubitemid 38264021)
45. Xu, F. et al. Structure of an agonist-bound human A2A adenosine receptor. Science 332, 322-327 (2011).
46. Rasmussen, S. G. et al. Structure of a nanobody-stabilized active state of the b2 adrenoceptor. Nature 469, 175-180 (2011).
47. Newstead, S., Kim, H., von Heijne, G., Iwata, S. & Drew, D. High-throughput fluorescent-based optimization of eukaryotic membrane protein overexpression and purification in Saccharomyces cerevisiae. Proc. Natl Acad. Sci. USA 104, 13936-13941 (2007). (Pubitemid 350003316)
48. Cherezov, V., Peddi, A., Muthusubramaniam, L., Zheng, Y. F. & Caffrey, M. A robotic system for crystallizing membrane and soluble proteins in lipidic mesophases. Acta Crystallogr. D 60, 1795-1807 (2004). (Pubitemid 41079701)
49. Aishima, J. et al. High-speed crystal detection and characterization using a fastreadout detector. Acta Crystallogr. D 66, 1032-1035 (2010).
50. Winter, G. xia2: an expert system for macromolecular crystallography data reduction. J. Appl. Cryst. 43, 186-190 (2010).
51. Leslie, A. G. W. Recent changes to the MOSFLM package for processing film and image plate data. Joint CCP4 ESF-EACMB Newslet. Protein Crystallogr. No. 26 (1992).
52. Evans, P. Scaling and assessment of data quality. Acta Crystallogr. D 62, 72-82 (2006).
53. McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Cryst. 40, 658-674 (2007). (Pubitemid 47080256)
54. Skubák, P., Murshudov, G. N. & Pannu, N. S. Direct incorporation of experimental phase informationinmodel refinement. Acta Crystallogr.D60,2196-2201(2004). (Pubitemid 41742771)
55. Murshudov, G. N., Vagin, A. A. & Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D 53, 240-255 (1997). (Pubitemid 27235885)
56. Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and Development of Coot. Acta Crystallogr. D 66, 486-501 (2010).
57. Abagyan, R., Orry, A., Raush, E. & Totrov, M. ICMManual v.3.0 (MolSoft LLC, 2011).
58. Totrov, M. & Abagyan, R. Derivation of sensitive discrimination potential for virtual ligand screening. Proceedings of the third annual international conference on computational molecular biology 312-317 (1999).
59. Abagyan, R. & Totrov, M. Biased probability Monte Carlo conformational searches and electrostatic calculations for peptides and proteins. J. Mol. Biol. 235, 983-1002 (1994). (Pubitemid 24047836)